Additional pathogenic variants included DNMT3A, TET2, ASXL1, JAK2, and SH2B3. All three patients were treated with AML-directed therapy (decitabine/venetoclax or liposomal cytarabine/daunorubicin). The gene discussed is JAK2; the disease is acute myeloid leukemia.